MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Study ID
NCT02575339

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Terminated

Trial Acronym

Trial Summary

This is an open label, multi-center, randomized phase I/II study of MLN0128 versus standard sorafenib. Eligible subjects in the phase I trial will receive MLN0128 in escalating doses. Eligible subjects in the phase II trial will be 1:1 randomized to either the MLN0128 arm or the sorafenib arm.

More informations

Trial Starting Date

Jul 18,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit